Cited 1 times in
Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이유미 | - |
dc.contributor.author | 홍남기 | - |
dc.contributor.author | 신성재 | - |
dc.date.accessioned | 2024-01-31T05:44:55Z | - |
dc.date.available | 2024-01-31T05:44:55Z | - |
dc.date.issued | 2023-12 | - |
dc.identifier.issn | 0937-941X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197872 | - |
dc.description.abstract | In this study, romosozumab demonstrated significantly greater improvement in trabecular bone score compared to denosumab therapy in postmenopausal women previously treated with antiresorptive agents. Notably, in patients previously treated with anti-resorptive agents, treatment with romosozumab resulted in similar increases in trabecular bone score compared to that of drug-naive patients.PurposeRomosozumab significantly increases bone mineral density (BMD) and rapidly reduces fracture risk. Whether romosozumab can improve the spinal trabecular bone score (TBS) as a bone quality indicator merits further investigation.MethodsData for postmenopausal women starting romosozumab or denosumab treatment at Severance Hospital, Korea, were analyzed. Romosozumab and denosumab groups were 1:1 matched using propensity scores, considering relevant covariates. Good responders were defined as those with TBS improvement of 5.8% or greater.ResultsOverall, 174 patients (romosozumab, n = 87; denosumab, n = 87) were analyzed. Matched groups did not differ in age (64 years), weight, height, previous fracture (38%), lumbar spine or femoral neck BMD (T-score, -3.4 and -2.6, respectively), or prior bisphosphonate or selective estrogen receptor modulator (SERM) exposure (50%). The romosozumab group exhibited a greater increase in lumbar spine BMD (15.2% vs. 6.9%, p < 0.001) and TBS (3.7% vs. 1.7%, p = 0.013) than the denosumab group. In patients transitioning from bisphosphonate or SERM, romosozumab users showed greater improvement in TBS compared to denosumab users (3.9% versus 0.8%, P = 0.006); the drug-naive group showed no significant difference (3.6% versus 2.7%, P = 0.472). The romosozumab group had a higher proportion of good responders than the denosumab group (33.3% vs. 18.4%, p = 0.024). Romosozumab therapy for 12 months resulted in 3.8-fold higher odds of a good response in TBS than denosumab after covariate adjustment (adjusted odds ratio 3.85, p = 0.002).ConclusionRomosozumab could improve bone mass and bone quality, measured by TBS, in postmenopausal osteoporosis, particularly as a subsequent regimen in patients previously taking anti-resorptive agents. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer International | - |
dc.relation.isPartOf | OSTEOPOROSIS INTERNATIONAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Cancellous Bone | - |
dc.subject.MESH | Denosumab / pharmacology | - |
dc.subject.MESH | Denosumab / therapeutic use | - |
dc.subject.MESH | Diphosphonates | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fractures, Bone* / chemically induced | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lumbar Vertebrae | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Osteoporosis, Postmenopausal* / chemically induced | - |
dc.subject.MESH | Osteoporosis, Postmenopausal* / drug therapy | - |
dc.subject.MESH | Selective Estrogen Receptor Modulators | - |
dc.title | Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Namki Hong | - |
dc.contributor.googleauthor | Sungjae Shin | - |
dc.contributor.googleauthor | Seunghyun Lee | - |
dc.contributor.googleauthor | Yumie Rhee | - |
dc.identifier.doi | 10.1007/s00198-023-06889-2 | - |
dc.contributor.localId | A03012 | - |
dc.contributor.localId | A04388 | - |
dc.relation.journalcode | J02451 | - |
dc.identifier.eissn | 1433-2965 | - |
dc.identifier.pmid | 37596432 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s00198-023-06889-2 | - |
dc.subject.keyword | Bone mineral density | - |
dc.subject.keyword | Denosumab | - |
dc.subject.keyword | Osteoporosis | - |
dc.subject.keyword | Postmenopause | - |
dc.subject.keyword | Romosozumab | - |
dc.subject.keyword | Trabecular bone score | - |
dc.contributor.alternativeName | Rhee, Yumie | - |
dc.contributor.affiliatedAuthor | 이유미 | - |
dc.contributor.affiliatedAuthor | 홍남기 | - |
dc.citation.volume | 34 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2059 | - |
dc.citation.endPage | 2067 | - |
dc.identifier.bibliographicCitation | OSTEOPOROSIS INTERNATIONAL, Vol.34(12) : 2059-2067, 2023-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.